269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群 [臨床試験数:20,薬物数:26(DrugBank:10),標的遺伝子数:12,標的パスウェイ数:90

Searched query = "Pyogenic arthritis", "Pyoderma gangrenosum", "Acne syndrome", "PAPA syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-002920-41-DE04/01/201224/08/2011Stelara® (Ustekinumab) treatment in Patients with Pyoderma gangrenosumOpen-label Trial of Stelara® (Ustekinumab) In Patients with Pyoderma gangrenosum – an open, non-placebo controlled pilot study with 10 patients. - SPG-Trial Patients with a clinical diagnosis of Pyoderma gangrenosum
MedDRA version: 14.1Level: LLTClassification code 10037634Term: Pyoderma gangenosumSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
Trade Name: Stelara
Product Name: Ustekinumab
Other descriptive name: USTEKINUMAB
University Hospital TübingenNULLNot RecruitingFemale: yes
Male: yes
Germany